{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:08:23Z","timestamp":1776877703833,"version":"3.51.2"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.thromres.2022.02.009","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T08:28:29Z","timestamp":1653553709000},"page":"S77-S83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S1","title":["Vaccine-induced immune thrombotic thrombocytopenia and patients with cancer"],"prefix":"10.1016","volume":"213","author":[{"given":"Jean M.","family":"Connors","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Iba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2022.02.009_bb0005","unstructured":"https:\/\/coronavirus.jhu.edu\/map.html."},{"issue":"26","key":"10.1016\/j.thromres.2022.02.009_bb0010","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1056\/NEJMc2102507","article-title":"Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated persons","volume":"385","author":"Kissler","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.thromres.2022.02.009_bb0015","doi-asserted-by":"crossref","first-page":"9131","DOI":"10.3390\/ijms22179131","article-title":"Possible link between higher transmissibility of alpha, kappa and delta variants of SARS-CoV-2 and increased structural stability of its spike protein and hACE2 affinity","volume":"22","author":"Kumar","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"10249","key":"10.1016\/j.thromres.2022.02.009_bb0020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.thromres.2022.02.009_bb0025","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.thromres.2022.02.009_bb0030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.thromres.2022.02.009_bb0035","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.thromres.2022.02.009_bb0040","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2022.02.009_bb0045","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2107058","article-title":"Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines","author":"Thompson","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10241","key":"10.1016\/j.thromres.2022.02.009_bb0050","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.thromres.2022.02.009_bb0055","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Del Molino Del Barrio","year":"2021","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.thromres.2022.02.009_bb0060","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.annonc.2021.04.020","article-title":"Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients","volume":"32","author":"Palich","year":"2021","journal-title":"Ann. Oncol."},{"issue":"Suppl 2","key":"10.1016\/j.thromres.2022.02.009_bb0065","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1016\/S0049-3848(07)70143-3","article-title":"Cancer, thrombosis and heparin-induced thrombocytopenia","volume":"120","author":"Prandoni","year":"2007","journal-title":"Thromb Res."},{"issue":"11","key":"10.1016\/j.thromres.2022.02.009_bb0070","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1111\/jth.13813","article-title":"Autoimmune heparin-induced thrombocytopenia","volume":"15","author":"Greinacher","year":"2017","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2022.02.009_bb0075","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMcp1411910","article-title":"Clinical practice. Heparin-induced thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.thromres.2022.02.009_bb0080","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.V76.2.336.336","article-title":"Structural and functional comparison of the genes for human platelet factor 4 and PF4alt","volume":"76","author":"Eisman","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.02.009_bb0085","doi-asserted-by":"crossref","unstructured":"Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.N Engl J Med. doi:10.1056\/NEJMoa2104840.","DOI":"10.1056\/NEJMoa2104840"},{"issue":"22","key":"10.1016\/j.thromres.2022.02.009_bb0090","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.thromres.2022.02.009_bb0095","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.thromres.2022.02.009_bb0100","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2021.7517","article-title":"US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021","volume":"325","author":"See","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2022.02.009_bb0105","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/jth.15362","article-title":"Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination","volume":"19","author":"Platton","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"19","key":"10.1016\/j.thromres.2022.02.009_bb0110","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1056\/NEJMc2112760","article-title":"Decline in pathogenic antibodies over time in VITT","volume":"385","author":"Sch\u00f6nborn","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"39","key":"10.1016\/j.thromres.2022.02.009_bb0115","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1093\/eurheartj\/ehab506","article-title":"Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia","volume":"42","author":"Holm","year":"2021","journal-title":"Eur Heart J."},{"key":"10.1016\/j.thromres.2022.02.009_bb0120","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia (VITT)","author":"Greinacher","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2022.02.009_bb0125","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s41467-019-09160-7","article-title":"Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia","volume":"10","author":"Perdomo","year":"2019","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.thromres.2022.02.009_bb0130","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s11239-020-02324-z","article-title":"Neutrophil extracellular traps and thrombosis in COVID-19","volume":"51","author":"Zuo","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2022.02.009_bb0135","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-021-03744-4","article-title":"Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia","volume":"596","author":"Huynh","year":"2021","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.thromres.2022.02.009_bb0140","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.thromres.2022.02.009_bb0145","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMc2112974","article-title":"Vaccine-induced thrombocytopenia with severe headache","volume":"385","author":"Salih","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.thromres.2022.02.009_bb0150","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1111\/jth.15346","article-title":"Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)","volume":"19","author":"Thaler","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"39","key":"10.1016\/j.thromres.2022.02.009_bb0155","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1093\/eurheartj\/ehab592","article-title":"Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score","volume":"42","author":"Hwang","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2022.02.009_bb0160","doi-asserted-by":"crossref","first-page":"772424","DOI":"10.3389\/fmed.2021.772424","article-title":"Case report: vaccine-induced immune thrombotic thrombocytopenia in a pancreatic cancer patient after vaccination with messenger RNA-1273","volume":"8","author":"Su","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.thromres.2022.02.009_bb0165","article-title":"Vaccine-induced immune thrombotic thrombocytopenia (VITT) - update on diagnosis and management considering different resources","author":"Greinacher","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"12","key":"10.1016\/j.thromres.2022.02.009_bb0170","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1111\/j.1538-7836.2011.04487.x","article-title":"Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series","volume":"9","author":"Warkentin","year":"2011","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2022.02.009_bb0175","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17474086.2019.1636645","article-title":"High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review","volume":"12","author":"Warkentin","year":"2019","journal-title":"Expert Rev Hematol."},{"issue":"3","key":"10.1016\/j.thromres.2022.02.009_bb0180","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/trf.15105","article-title":"Use of intravenous immunoglobulin G to treat spontaneous heparin-induced thrombocytopenia","volume":"59","author":"Irani","year":"2019","journal-title":"Transfusion"},{"issue":"11","key":"10.1016\/j.thromres.2022.02.009_bb0185","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1182\/blood.2021012479","article-title":"Tamam bakchoul; the use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Uzun","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.thromres.2022.02.009_bb0190","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1056\/NEJMc2109465","article-title":"Therapeutic plasma exchange in vaccine-induced immune thrombotic thrombocytopenia","volume":"385","author":"Patriquin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2022.02.009_bb0195","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.thromres.2021.09.017","article-title":"Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia","volume":"207","author":"Thaler","year":"2021","journal-title":"Thromb Res."},{"issue":"19","key":"10.1016\/j.thromres.2022.02.009_bb0200","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1056\/NEJMc2112760","article-title":"Decline in Pathogenic Antibodies over Time in VITT","volume":"385","author":"Sch\u00f6nborn","year":"2021","journal-title":"N Engl J Med."},{"issue":"15","key":"10.1016\/j.thromres.2022.02.009_bb0205","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMoa2110362","article-title":"Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings","volume":"385","author":"Thompson","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2022.02.009_bb0210","article-title":"VITT and second doses of Covid-19 vaccine","author":"Lacy","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2022.02.009_bb0215","unstructured":"https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/adverse-events.html."},{"key":"10.1016\/j.thromres.2022.02.009_bb0220","article-title":"Heterologous SARS-CoV-2 booster vaccinations - preliminary report","author":"Atmar","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.thromres.2022.02.009_bb0225","article-title":"Booster of mRNA-1273 vaccine reduces SARS-CoV-2 omicron escape from neutralizing antibodies","author":"Doria-Rose","year":"2021","journal-title":"medRxiv"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:48:10Z","timestamp":1758736090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384822000469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":45,"alternative-id":["S0049384822000469"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2022.02.009","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine-induced immune thrombotic thrombocytopenia and patients with cancer","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2022.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}